ACTELION PHARMACEUTICALS
Actelion Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of low molecular weight drugs for various medical needs. Its principal products include Tracleer, an orally available dual endothelin receptor antagonist, approved as a therapy for pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart; and Zavesca, in-licensed from Oxford GlycoSciences, an oral medication indi... cated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. The company also offers Ventavis, an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation. In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system disorders. In addition, it has an exclusive worldwide alliance with Merck & Co, Inc. to discover, develop, and market new classes of renin inhibitors for patients suffering from cardio-renal diseases. Actelion markets Tracleer in the United States, the European Union, Japan, Canada, Australia, and Switzerland. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.
ACTELION PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
1997-01-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.actelion.com
Total Employee:
5001+
Status:
Active
Contact:
(416) 156-5656
Total Funding:
12 M USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt Mobile Non Scaleable Content HSTS Cloudflare Hosting Nginx Common Name Invalid ASP.NET Apache 2.4 Ubuntu
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Novexel
Novexel SA, a pharmaceutical company, engages in the discovery and development of antibacterial and antifungal agents to treat bacterial
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
TCD Pharma
TCD Pharma is a biotechnology company engaged in the discovery, development and commercialization of oncology drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2013-07-31 | Ceptaris Therapeutics | Ceptaris Therapeutics acquired by Actelion Pharmaceuticals | 250 M USD |
| 2010-07-20 | Trophos | Trophos acquired by Actelion Pharmaceuticals | 10 M EUR |
| 2006-11-20 | Cotherix | Cotherix acquired by Actelion Pharmaceuticals | 420 M USD |
| 2003-10-01 | Axovan | Axovan acquired by Actelion Pharmaceuticals | N/A |
Investors List
Sofinnova Investments
Sofinnova Investments investment in Venture Round - Actelion Pharmaceuticals
Reference Capital SA
Reference Capital SA investment in Venture Round - Actelion Pharmaceuticals
Atlas Venture
Atlas Venture investment in Venture Round - Actelion Pharmaceuticals
HealthCap
HealthCap investment in Venture Round - Actelion Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-01 | Quotient Limited Announces Christian Albrich as Chief People Officer |
More informations about "Actelion Pharmaceuticals"
Actelion Pharmaceuticals - Crunchbase Company …
In addition, Actelion evaluates various compounds in various phases of clinical development for treating cardiovascular, cardiopulmonary, immunological, and infectious diseases, as well as metabolic and central nervous system …See details»
Actelion - companieshistory.com
May 12, 2014 Actelion Pharmaceuticals Ltd. – history, company profile (overview) and corporate video Actelion Pharmaceuticals Ltd. is a pharmaceutical and biotechnology company, …See details»
6 questions investors may have about - Johnson
May 16, 2017 Johnson & Johnson recently announced it was making a significant business move: the acquisition of Actelion, a biopharmaceutical company based in Switzerland. The all-cash, $30 billion deal—which is …See details»
Actelion (now Janssen Pulmonary Hypertension)
Actelion (now Janssen Pulmonary Hypertension) | 54,408 followers on LinkedIn. We're now part of Janssen. For future updates, please visit our LinkedIn channel: 'Janssen Pharmaceutical ...See details»
Johnson & Johnson Announces Completion of Acquisition of …
NEW BRUNSWICK, N.J. – June 16, 2017 – Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Actelion Ltd for a total purchase price of approximately $30 …See details»
ACTELION’S COMPANY PROFILE - GlobeNewswire
ACTELION’S COMPANY PROFILE Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with …See details»
Actelion Pharmaceuticals Ltd. - Swiss Biotech
Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of …See details»
Actelion - Swiss Biotech
Headquartered in Allschwil, Actelion is part of the Johnson & Johnson Family of Companies. Its ground-breaking research and medicines have been a key contributor to improve the lives of …See details»
Actelion Pharmaceuticals Company Profile - Office Locations ...
Actelion Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development, and commercialization of innovative treatments to serve high unmet medical …See details»
Team Actelion. In the 1980s, hundreds of …
May 26, 2015 By the end of 2003, Actelion had made an initial public offering of stock, introduced a first-in-class blockbuster therapeutic product, and set up a global marketing organization. In 2004, the ...See details»
Inside View: Actelion Pharmaceuticals - Nature
Sep 30, 2015 In 1997 four scientists left behind a secure career in identifying and testing new drugs at the pharmaceutical giant, F. Hoffman-La Roche, to set up their own company, …See details»
Actelion Pharmaceuticals - Overview, News & Similar companies ...
Who is Actelion Pharmaceuticals. Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, developme nt …See details»
Actelion | Company Overview & News - Forbes
Actelion Ltd is a Switzerland-based biopharmaceutical Company that focuses on the discovery, development and commercialization of treatments. Its products specialize in conditions related …See details»
Actelion Pharmaceuticals - Contacts, Employees, Board Members, …
Actelion Pharmaceuticals has 10 board members and advisors, including John J. Greisch. Contacts. Edit Contacts Section. Job Department. Protected Content. Vice President - Head of …See details»
Johnson & Johnson to buy Swiss biotech company Actelion for …
Jan 26, 2017 J&J is offering Actelion’s shareholders $30bn in cash — considerably more than investors had been expecting — and has also agreed to a complex deal that will result in the …See details»
Martine Clozel - Wikipedia
Clozel studied at the University of Nancy and the University of California in San Francisco.She also attended further training in physiology and pharmacology at McGill University. [2]In 1997, …See details»
J&J boss’s long quest ends with $30bn Actelion deal - Financial …
Jan 26, 2017 The long hunt for Actelion; J&J first approached Actelion about a year ago, and finally sealed a deal after months of intensive courting, writes James Fontanella-Khan in New …See details»
Actelion - VentureRadar
"Actelion is part of the Johnson & Johnson Family of Companies. We are leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 20 years of experience in …See details»
J&J completes Actelion acquisition for $30bn
Jun 18, 2017 The deal is expected to expand Janssen’s portfolio with Actelion PAH franchise’s differentiated in-market medicines and late-stage therapies such as Opsumit, Uptravi and …See details»